Sign in

    Peter Halesworth

    Research Analyst at Heng Ren Investments

    Peter Halesworth is the Founder and Portfolio Manager at Heng Ren Partners, specializing in activist investment in U.S.-listed microcap Chinese companies such as Sinovac Biotech and Kingold Jewelry. He has more than 20 years of investment experience, with his firm recognized for successful interventions that have driven operational and governance improvements, earning accolades like Acquisition International's 2016 Best China-Focused Long-Term Active Asset Manager award. Halesworth began his career in international investment banking and journalism, including establishing Dow Jones’ Indonesia bureau in 1994, before founding Heng Ren in 2013. He holds a bachelor's degree from Vassar College and is known for authoring research on regulatory gaps for U.S. investors in Chinese companies, though there is no public record of FINRA registration or securities licenses.

    Peter Halesworth's questions to SINOVAC BIOTECH (SVA) leadership

    Peter Halesworth's questions to SINOVAC BIOTECH (SVA) leadership • Q3 2016

    Question

    Peter Halesworth of Heng Ren Investments inquired about Q4 and 2017 sales guidance for the EV71 vaccine, its average price per dose, and gross margin. He also questioned the high costs related to the company's privatization, asking for a breakdown of Q3 and year-to-date expenses.

    Answer

    Helen Yang, Investor Relations Director, stated that EV71 sales would be a key contributor in Q4 but declined to give 2017 guidance due to regulatory policy changes. She provided the EV71 price per dose as 168 for vial and 188 for pre-filled syringe presentations. Regarding privatization, she confirmed the $733,000 Q3 cost was for financial and legal advisors and that year-to-date expenses were over $1 million.

    Ask Fintool Equity Research AI

    Peter Halesworth's questions to SINOVAC BIOTECH (SVA) leadership • Q4 2015

    Question

    Peter Halesworth from Heng Ren Investments L.P. inquired about the expected timing for receiving provincial orders for the EV71 vaccine and whether Sinovac's product was the sole one available on the market.

    Answer

    CEO Weidong Yin, via an interpreter, confirmed that another company also has an approved EV71 vaccine and that Sinovac anticipates receiving orders once its vaccine obtains the necessary lot release. Investor Relations Director Helen Yang specified that the government release is expected by the end of the second quarter of 2016.

    Ask Fintool Equity Research AI